Muscle Relaxants

  • Donald B. Hoover


The vast majority of drugs that are used to produce relaxation of skeletal muscle achieve this effect by an action at some point in the neuronal pathways involved in muscle regulation. Although the skeletal muscles are under voluntary control, there is an abundance of neuronal circuitry which participates in the generation of smooth, coordinated movement. All of the neural information is ultimately channeled through the alpha motoneurons which are responsible for causing contraction of skeletal muscle cells. To fully appreciate the actions of muscle relaxants, it will be necessary to briefly review certain aspects of the neuroregulation of skeletal muscles.


Skeletal Muscle Muscle Relaxant Neuromuscular Junction Nicotinic Receptor Muscle Spindle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bowman WC, Rand MJ: Textbook of Pharmacology, ed 2. London, Blackwell Scientific Publications, 1980.Google Scholar
  2. 2.
    Colquhoun D: On the principles of postsynaptic action of neuromuscular blocking agents, in Kharkevich DA (ed): New Neuromuscular Blocking Agents. Berlin. Springer-Verlag, 1986, p 59.CrossRefGoogle Scholar
  3. 3.
    Bowman WC: Non-relaxant properties of neuromuscular blocking drugs. Br J Anaesth 54: 147–160, 1982.PubMedCrossRefGoogle Scholar
  4. 4.
    Kharkevich DA, Shoff VA: Antimuscarinic and ganglion-blocking activity of neuromuscular blocking agents, in Kharkevich DA (ed): New Neuromuscular Blocking Agents. Berlin, Springer-Verlag, 1986, p 191.CrossRefGoogle Scholar
  5. 5.
    AMA Drug Evaluations, ed 5. Chicago, American Medical Association, 1983.Google Scholar
  6. 6.
    Durant NN, Katz RL: Suxamethonium. Br J Anaesth 54: 195–208, 1982.PubMedCrossRefGoogle Scholar
  7. 7.
    Smith SE: Neuromuscular blocking drugs in man, in Zaimis E (ed): Neuromuscular Junction. Berlin, Springer-Verlag, 1976, p 593.Google Scholar
  8. 8.
    Zamis E, Head S: Depolarizing neuromuscular blocking drugs, in Zaimis E (ed): Neuromuscular Junction. Berlin, Springer-Verlag, 1976, p 365.Google Scholar
  9. 9.
    The top 200 Rx drugs of 1986. Am Druggist, February 1987, pp 19–32.Google Scholar
  10. 10.
    Martin IL: The benzodiazepine receptor: functional complexity. TIPS 5: 343–347, 1984.Google Scholar
  11. 11.
    Guidotti A, Forchetti CM, Corda MG, et al: Isolation, characterization, and purification to homogeneity of an endogenous polypeptide with agonistic action on benzodiazepine receptors. Proc Natl Acad Sci USA 80: 3531–3535, 1983.PubMedCrossRefGoogle Scholar
  12. 12.
    Tseng T-C, Wang SC: Locus of action of centrally acting muscle relaxants, diazepam and tybamate. J Pharmacol Exp Ther 178: 350–360, 1971.PubMedGoogle Scholar
  13. 13.
    Hyman SE, Arana GW: Handbook of Psychiatric Drug Therapy. Boston, Little, Brown, 1987.Google Scholar
  14. 14.
    Smith CM: Relaxants of skeletal muscle, in Roots WS, Hofmann FG (eds): Physiological Pharmacology. New York, Academic Press, vol 2, 1965, p 1.Google Scholar
  15. 15.
    Kurachi M, Aihara H: Effect of a muscle relaxant, chlorphenesin carbamate, on spinal neurons of rats. Japan J Pharmacol 36: 7–13, 1984.CrossRefGoogle Scholar
  16. 16.
    Share NN, McFarlane CS: Cyclobenzaprine: a novel centrally acting skeletal muscle relaxant. Neuropharmacology 14: 675–684, 1975.PubMedCrossRefGoogle Scholar
  17. 17.
    Share NN: Cyclobenzaprine: effect on segmental monosynaptic and tonic vibration reflexes in the cat. Neuropharmacology 17: 721–727, 1978.PubMedCrossRefGoogle Scholar
  18. 18.
    Barnes CD, Adams WL: Effects of cyclobenzaprine on interneurones of the spinal cord. Neuropharmacology 17: 445–450, 1978.PubMedCrossRefGoogle Scholar
  19. 19.
    Barnes CD, Fung SJ, Gintautas J: Brainstem noradrenergic system depression by cyclobenzaprine. Neuropharmacology 19: 221–224, 1980.PubMedCrossRefGoogle Scholar
  20. 20.
    Nibbelink DW, Strickland SC: Cyclobenzaprine (Flexeril): report of a postmarketing surveillance program. Curr Therap Res 28: 894–903, 1980.Google Scholar
  21. 21.
    Elenbaas JK: Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm 37: 1313–1323, 1980.PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1988

Authors and Affiliations

  • Donald B. Hoover
    • 1
  1. 1.Department of Pharmacology, Quillen-Dishner College of MedicineEast Tennessee State UniversityJohnson CityUSA

Personalised recommendations